Another month, another 2 expanded FDA-approvals: nivolumab/ipilimumab for malignant pleural mesothelioma and pembrolizumab for relapsed/refractory classical Hodgkin's lymphoma.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
